LIFITEGRAST | N208073 | BAUSCH AND LOMB INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2021-11-23 | Terminated 2023-04-20 | — | |
| D. Del. | 2021-06-30 | Terminated 2023-01-19 | — | |
Novartis Pharmaceuticals Corporation v. Aurobindo Pharma Ltd. et al 15 patentsANDA 215063lifitegrast | D. Del. | 2020-10-23 | Terminated 2023-03-27 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$11.83
per ea
Lowest NADAC/Unit
$11.83
per ea
Brand NDCs
2
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00078091112XIIDRA 5% EYE DROPS | $11.83 | EA | Brand | — | 2026-06-17 |
| 24208091112XIIDRA 5% EYE DROPS | $11.83 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 7314938Newly listed — daily FDA feed, not yet in monthly Orange Book edition | Jun 25, 2029 | — | Yes | Yes | — | — |
| 8084047 | May 17, 2026 | — | Yes | Yes | — | — |
| 8168655 | May 9, 2029 | — | — | — | — | |
| 8367701 | Apr 15, 2029 | — | — | Yes | — | |
| 8592450 | May 17, 2026 | — | — | — | — | |
| 8927574 | Nov 12, 2030 | — | — | Yes | — | — |
| 9085553 | Jul 25, 2033 | — | — | Yes | — | — |
| 9353088 | Oct 21, 2030 | — | — | Yes | — | — |
| 9447077 | Apr 15, 2029 | — | — | — | — | |
| 9890141 | Oct 21, 2030 | — | Yes | — | — | — |
| 11058677 | Dec 18, 2033 | — | — | Yes | — | — |